1. Home
  2. CLRO vs CVKD Comparison

CLRO vs CVKD Comparison

Compare CLRO & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ClearOne Inc. (DE)

CLRO

ClearOne Inc. (DE)

N/A

Current Price

$3.42

Market Cap

14.4M

Sector

Technology

ML Signal

N/A

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$5.59

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLRO
CVKD
Founded
1983
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.4M
13.8M
IPO Year
2018
2022

Fundamental Metrics

Financial Performance
Metric
CLRO
CVKD
Price
$3.42
$5.59
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$13.00
AVG Volume (30 Days)
5.9K
43.8K
Earning Date
05-18-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.94
EPS
N/A
N/A
Revenue
$46,067,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
11.59
N/A
52 Week Low
$0.29
$4.21
52 Week High
$15.42
$17.00

Technical Indicators

Market Signals
Indicator
CLRO
CVKD
Relative Strength Index (RSI) 45.59 50.88
Support Level $2.71 $5.13
Resistance Level $3.77 $6.09
Average True Range (ATR) 0.18 0.54
MACD 0.10 0.14
Stochastic Oscillator 66.67 67.72

Price Performance

Historical Comparison
CLRO
CVKD

About CLRO ClearOne Inc. (DE)

ClearOne Inc is a communications solutions company, which is engaged in designing, developing, and selling conferencing, collaboration, streaming, and digital signage solutions for audio, video, and visual communication. It sells its commercial products to end-users predominantly through a network of independent distributors, who in turn sell its products to dealers, systems integrators, and other resellers. Its products include DSP mixers, amplifiers, Video walls, professional cameras, and professional microphones among others. Geographically the firm has its business presence across the United States and international markets.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Share on Social Networks: